Publicar

Mercury77
Mercury77
#ModernaQ3VaccineSales My take on Moderna (MRNA) Q3: I am leaning YES on beating earnings. The bar is very low — consensus is -$1.10 EPS on ~$890M revenue, vs -$0.51 on $1.02B last year. In Q2 they already beat with -$1.97 on $145M revenue vs $103M expected. The real story is not COVID anymore, it's the cancer vaccine data. That is why the stock is up almost 8x from its low this year.

Descargo de responsabilidad: el contenido de OKX Orbit se brinda únicamente con fines informativos. Más información

Respuestas

Aún no hay comentarios. ¡Sé el primero en responder!